Interaction of Tomudex with radiation in vitro and in vivo

Beverly A. Teicher, Gulshan Ara, Ying Nan Chen, Abram Recht, C. Norman Coleman

Research output: Contribution to journalArticle

Abstract

The potential of the thymidylate synthase inhibitor, Tomudex to interact with ionizing radiation was assessed in vitro and in vivo in comparison with 5-fluorouracil. A concentration of 1 μM Tomudex decreased the shoulder of the radiation survival curves for normally oxygenated and hypoxic human HT- 29 colon carcinoma cells and human SCC-25 head and neck squamous carcinoma cells, resulting in enhancement ratios of 10 and 2.8 for normally oxygenated and hypoxic HT-29 cells at 5 Gray, respectively, and enhancement ratios of 19.5 and 2.7 for normally oxygenated and hypoxic SCC-25 cell at 5 Gray, respectively. Two schedules of Tomudex administered to animals bearing the Lewis lung carcinoma resulted in additive tumor growth delay with the fractionated radiation therapy. In nude mice bearing the HT-29 colon carcinoma grown as a xenograft, administration of Tomudex daily for 5 days on a 1 or 2-week schedule resulted in increased tumor growth delay along with fractionated radiation therapy on the same schedules. However, administration of Tomudex intermittently on a 2-week schedule appeared to be more interactive with daily fractionated radiation therapy on the 2-week schedule. In each assay, the results obtained with Tomudex were equal to or exceeded those obtained with 5-fluorouracil. These findings indicate that clinical trial of Tomudex along with fractionated radiation therapy is warranted.

Original languageEnglish (US)
Pages (from-to)437-442
Number of pages6
JournalInternational Journal of Oncology
Volume13
Issue number3
StatePublished - Sep 1998
Externally publishedYes

Fingerprint

Radiation
Appointments and Schedules
Radiotherapy
Fluorouracil
Colon
Lewis Lung Carcinoma
Carcinoma
Thymidylate Synthase
HT29 Cells
Growth
Ionizing Radiation
raltitrexed
In Vitro Techniques
Heterografts
Nude Mice
Neoplasms
Clinical Trials
Survival

Keywords

  • Colon carcinoma cells
  • Head and neck squamous carcinoma cells
  • Thymidylate synthase inhibitor
  • Tomudex

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Teicher, B. A., Ara, G., Chen, Y. N., Recht, A., & Coleman, C. N. (1998). Interaction of Tomudex with radiation in vitro and in vivo. International Journal of Oncology, 13(3), 437-442.

Interaction of Tomudex with radiation in vitro and in vivo. / Teicher, Beverly A.; Ara, Gulshan; Chen, Ying Nan; Recht, Abram; Coleman, C. Norman.

In: International Journal of Oncology, Vol. 13, No. 3, 09.1998, p. 437-442.

Research output: Contribution to journalArticle

Teicher, BA, Ara, G, Chen, YN, Recht, A & Coleman, CN 1998, 'Interaction of Tomudex with radiation in vitro and in vivo', International Journal of Oncology, vol. 13, no. 3, pp. 437-442.
Teicher BA, Ara G, Chen YN, Recht A, Coleman CN. Interaction of Tomudex with radiation in vitro and in vivo. International Journal of Oncology. 1998 Sep;13(3):437-442.
Teicher, Beverly A. ; Ara, Gulshan ; Chen, Ying Nan ; Recht, Abram ; Coleman, C. Norman. / Interaction of Tomudex with radiation in vitro and in vivo. In: International Journal of Oncology. 1998 ; Vol. 13, No. 3. pp. 437-442.
@article{1aa0e202efb7403fa1cb2a84036dec1f,
title = "Interaction of Tomudex with radiation in vitro and in vivo",
abstract = "The potential of the thymidylate synthase inhibitor, Tomudex to interact with ionizing radiation was assessed in vitro and in vivo in comparison with 5-fluorouracil. A concentration of 1 μM Tomudex decreased the shoulder of the radiation survival curves for normally oxygenated and hypoxic human HT- 29 colon carcinoma cells and human SCC-25 head and neck squamous carcinoma cells, resulting in enhancement ratios of 10 and 2.8 for normally oxygenated and hypoxic HT-29 cells at 5 Gray, respectively, and enhancement ratios of 19.5 and 2.7 for normally oxygenated and hypoxic SCC-25 cell at 5 Gray, respectively. Two schedules of Tomudex administered to animals bearing the Lewis lung carcinoma resulted in additive tumor growth delay with the fractionated radiation therapy. In nude mice bearing the HT-29 colon carcinoma grown as a xenograft, administration of Tomudex daily for 5 days on a 1 or 2-week schedule resulted in increased tumor growth delay along with fractionated radiation therapy on the same schedules. However, administration of Tomudex intermittently on a 2-week schedule appeared to be more interactive with daily fractionated radiation therapy on the 2-week schedule. In each assay, the results obtained with Tomudex were equal to or exceeded those obtained with 5-fluorouracil. These findings indicate that clinical trial of Tomudex along with fractionated radiation therapy is warranted.",
keywords = "Colon carcinoma cells, Head and neck squamous carcinoma cells, Thymidylate synthase inhibitor, Tomudex",
author = "Teicher, {Beverly A.} and Gulshan Ara and Chen, {Ying Nan} and Abram Recht and Coleman, {C. Norman}",
year = "1998",
month = "9",
language = "English (US)",
volume = "13",
pages = "437--442",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "3",

}

TY - JOUR

T1 - Interaction of Tomudex with radiation in vitro and in vivo

AU - Teicher, Beverly A.

AU - Ara, Gulshan

AU - Chen, Ying Nan

AU - Recht, Abram

AU - Coleman, C. Norman

PY - 1998/9

Y1 - 1998/9

N2 - The potential of the thymidylate synthase inhibitor, Tomudex to interact with ionizing radiation was assessed in vitro and in vivo in comparison with 5-fluorouracil. A concentration of 1 μM Tomudex decreased the shoulder of the radiation survival curves for normally oxygenated and hypoxic human HT- 29 colon carcinoma cells and human SCC-25 head and neck squamous carcinoma cells, resulting in enhancement ratios of 10 and 2.8 for normally oxygenated and hypoxic HT-29 cells at 5 Gray, respectively, and enhancement ratios of 19.5 and 2.7 for normally oxygenated and hypoxic SCC-25 cell at 5 Gray, respectively. Two schedules of Tomudex administered to animals bearing the Lewis lung carcinoma resulted in additive tumor growth delay with the fractionated radiation therapy. In nude mice bearing the HT-29 colon carcinoma grown as a xenograft, administration of Tomudex daily for 5 days on a 1 or 2-week schedule resulted in increased tumor growth delay along with fractionated radiation therapy on the same schedules. However, administration of Tomudex intermittently on a 2-week schedule appeared to be more interactive with daily fractionated radiation therapy on the 2-week schedule. In each assay, the results obtained with Tomudex were equal to or exceeded those obtained with 5-fluorouracil. These findings indicate that clinical trial of Tomudex along with fractionated radiation therapy is warranted.

AB - The potential of the thymidylate synthase inhibitor, Tomudex to interact with ionizing radiation was assessed in vitro and in vivo in comparison with 5-fluorouracil. A concentration of 1 μM Tomudex decreased the shoulder of the radiation survival curves for normally oxygenated and hypoxic human HT- 29 colon carcinoma cells and human SCC-25 head and neck squamous carcinoma cells, resulting in enhancement ratios of 10 and 2.8 for normally oxygenated and hypoxic HT-29 cells at 5 Gray, respectively, and enhancement ratios of 19.5 and 2.7 for normally oxygenated and hypoxic SCC-25 cell at 5 Gray, respectively. Two schedules of Tomudex administered to animals bearing the Lewis lung carcinoma resulted in additive tumor growth delay with the fractionated radiation therapy. In nude mice bearing the HT-29 colon carcinoma grown as a xenograft, administration of Tomudex daily for 5 days on a 1 or 2-week schedule resulted in increased tumor growth delay along with fractionated radiation therapy on the same schedules. However, administration of Tomudex intermittently on a 2-week schedule appeared to be more interactive with daily fractionated radiation therapy on the 2-week schedule. In each assay, the results obtained with Tomudex were equal to or exceeded those obtained with 5-fluorouracil. These findings indicate that clinical trial of Tomudex along with fractionated radiation therapy is warranted.

KW - Colon carcinoma cells

KW - Head and neck squamous carcinoma cells

KW - Thymidylate synthase inhibitor

KW - Tomudex

UR - http://www.scopus.com/inward/record.url?scp=0031858463&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031858463&partnerID=8YFLogxK

M3 - Article

C2 - 9683775

AN - SCOPUS:0031858463

VL - 13

SP - 437

EP - 442

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 3

ER -